* Marker Therapeutics Inc reported a quarterly adjusted loss of 29 cents per share for the quarter ended in January. The lone analyst forecast for the quarter was for a loss of 43 cents per share.
* Reported revenue was zero; analysts expected zero.
* Marker Therapeutics Inc's reported EPS for the quarter was a loss of 29 cents.
* The company reported a quarterly loss of $2.19 million.
* Marker Therapeutics Inc shares had fallen by 38.1% this quarter and lost 38.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 60.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Marker Therapeutics Inc is $11.75 This summary was machine generated from LSEG data August 15 at 07:38 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.43 -0.29 Beat
Mar. 31 2024 -0.25 -0.27 Missed
Comments